Adjuvant therapy for intrahepatic cholangiocarcinoma: The debate continues

Oncologist

Volumn 17, Issue 12, 2012, Pages 1504-1507

  Zhu, Andrew X ^a   Knox, Jennifer J ^b  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN; CAPECITABINE; CISPLATIN; CYTOKERATIN 19; CYTOKERATIN 7; FLUORODEOXYGLUCOSE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; ISOCITRATE DEHYDROGENASE; OXALIPLATIN; SMAD4 PROTEIN;

ADULT; ARTICLE; BILE DUCT CARCINOMA; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CASE REPORT; CELL INVASION; CHEMORADIOTHERAPY; CHOLECYSTECTOMY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; ECHOGRAPHY; FATIGUE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; LIVER RESECTION; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; METASTASIS; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SURVIVAL RATE; THROMBOEMBOLISM;

ADENOCARCINOMA; ADULT; ALPHA-FETOPROTEINS; BILE DUCTS, INTRAHEPATIC; BIOLOGICAL MARKERS; BIOPSY; CA-125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CARRIER PROTEINS; CHEMOTHERAPY, ADJUVANT; CHOLANGIOCARCINOMA; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; CYTOKINES; DEOXYCYTIDINE; FEMALE; FLUORODEOXYGLUCOSE F18; FLUOROURACIL; GLYCOPROTEINS; HEPATECTOMY; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-20; KERATINS; LIVER; LIVER NEOPLASMS; LYMPH NODE EXCISION; MAGNETIC RESONANCE IMAGING; PHENOTYPE; PORTAL VEIN; PREGNANCY; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 84871533496     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0432     Document Type: Article

References (15)

1. Poultsides GA, Zhu AX, Choti MA et al. Intrahepatic cholangiocarcinoma. Surg Clin North Am 2010;90:817-837.
2. Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. Hepatology 2011; 54:173-184.
3. Vauthey JN, Blumgart LH. Recent advances in the management of cholangiocarcinomas. Semin Liver Dis 1994;14:109-114.
4. Lazaridis KN, Gores GJ. Cholangiocarcinoma. Gastroenterology 2005;128: 1655-1667.
5. Valle J, Wasan H, Palmer DH et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010;362:1273-1281.
6. Shaib YH, Davila JA, McGlynn K et al. Rising incidence of intrahepatic cholangiocarcinoma in the United States: A true increase? J Hepatol 2004;40:472-477.
7. Borger DR, Tanabe KK, Fan KC et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. The Oncologist 2012;17:72-79.
8. Kipp BR, Voss JS, Kerr SE et al. Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. Hum Pathol 2012;43:1552-1558.
9. Wang P, Dong Q, Zhang C et al. Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. Oncogene 2012 Jul 23 [Epub ahead of print]. doi: 10.1038/onc.2012.315.
10. Endo I, Gonen M, Yopp AC et al. Intrahepatic cholangiocarcinoma: Rising frequency, improved survival, and determinants of outcome after resection. Ann Surg 2008;248:84-96.
11. de Jong MC, Nathan H, Sotiropoulos GC et al. Intrahepatic cholangiocarcinoma: An international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol 2011;29:3140-3145.
12. Fisher SB, Patel SH, Kooby DA et al. Lymphovascular and perineural invasion as selection criteria for adjuvant therapy in intrahepatic cholangiocarcinoma: A multi-institution analysis. HPB (Oxford) 2012;14:514-522.
13. Neoptolemos JP, Moore MJ, Cox TF et al. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: The ESPAC-3 periampullary cancer randomized trial. JAMA 2012;308:147-156.
14. Horgan AM, Amir E, Walter T et al. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol 2012;30:1934-1940.
15. Benson AB, 3rd, Abrams TA, Ben-Josef E et al. NCCN clinical practice guidelines in oncology: Hepatobiliary cancers. J Natl Compr Canc Netw 2009;7:350-391.